Literature DB >> 30220042

Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival.

S H Bakker1, W C H Jacobs2, W Pondaag2, H Gelderblom3, R A Nout4, P D S Dijkstra5, W C Peul2, C L A Vleggeert-Lankamp2.   

Abstract

BACKGROUND AND AIMS: The aim of this systematic review is to describe the epidemiology of chordoma and to provide a clear overview of clinical prognostic factors predicting progression-free and overall survival.
METHODS: Four databases of medical literature were searched. Separate searches were performed for each of the two objectives. Reference and citation tracking was performed. Papers were processed by two independent reviewers according to a protocol that included risk of bias analysis. Disagreement was resolved by discussion. Pooled analyses were planned if homogeneity of data would allow.
RESULTS: Incidence-incidence rates ranged between 0.18 and 0.84 per million persons per year and varied between countries and presumably between races. On average patients were diagnosed in their late fifties and gender data indicate clear male predominance. Two of the largest studies (n = 400 and n = 544) reported different anatomical distributions: one reporting the skull base and sacrococcygeal area affected in 32% and 29% of cases, whereas the other reporting that they were affected in 26% and 45% of cases, respectively. PROGNOSTIC FACTORS: Statistically significant adverse prognostic factors predicting progression-free and overall survival include female sex, older age, bigger tumour size, increasing extent of tumour invasion, non-total resection, presence of metastasis, local recurrence, and dedifferentiated histological subtype.
CONCLUSIONS: Incidence rate and anatomical distribution vary between countries and presumably between races. Most chordomas arise in the skull base and sacrococcygeal spine, and the tumour shows clear male predominance. Multiple adverse prognostic factors predicting progression-free and overall survival were identified in subgroups of patients. These slides can be retrieved under Electronic Supplementary Material.

Entities:  

Keywords:  Chordoma; Epidemiology; Prognosis; Survival; Systematic review

Mesh:

Year:  2018        PMID: 30220042     DOI: 10.1007/s00586-018-5764-0

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  44 in total

1.  Chordoma: incidence and survival patterns in the United States, 1973-1995.

Authors:  M L McMaster; A M Goldstein; C M Bromley; N Ishibe; D M Parry
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

2.  Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement.

Authors:  Damian Hoy; Peter Brooks; Anthony Woolf; Fiona Blyth; Lyn March; Chris Bain; Peter Baker; Emma Smith; Rachelle Buchbinder
Journal:  J Clin Epidemiol       Date:  2012-06-27       Impact factor: 6.437

3.  Prognostic factors in chordoma: role of postoperative radiotherapy.

Authors:  C Thieblemont; P Biron; F Rocher; D Bouhour; J Y Bobin; J P Gérard; J Y Blay
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

4.  Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas.

Authors:  Taohui Ouyang; Na Zhang; Yan Zhang; Jiantong Jiao; Jian Ren; Tao Huang; Jian Chen
Journal:  World Neurosurg       Date:  2013-01-05       Impact factor: 2.104

5.  Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy.

Authors:  Damien C Weber; Robert Malyapa; Francesca Albertini; Alessandra Bolsi; Ulrike Kliebsch; Marc Walser; Alessia Pica; Christophe Combescure; Antony J Lomax; Ralf Schneider
Journal:  Radiother Oncol       Date:  2016-05-28       Impact factor: 6.280

6.  Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma.

Authors:  A E Rosenberg; G P Nielsen; S B Keel; L G Renard; M M Fitzek; J E Munzenrider; N J Liebsch
Journal:  Am J Surg Pathol       Date:  1999-11       Impact factor: 6.394

7.  Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable.

Authors:  Wouter A Moojen; Carmen L A Vleggeert-Lankamp; Augustinus D G Krol; Sander P D Dijkstra
Journal:  Spine (Phila Pa 1976)       Date:  2011-05-01       Impact factor: 3.468

8.  Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma.

Authors:  A Terahara; A Niemierko; M Goitein; D Finkelstein; E Hug; N Liebsch; D O'Farrell; S Lyons; J Munzenrider
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-09-01       Impact factor: 7.038

9.  The surgical management of sacral chordomas.

Authors:  Joseph H Schwab; John H Healey; Peter Rose; Jorge Casas-Ganem; Patrick J Boland
Journal:  Spine (Phila Pa 1976)       Date:  2009-11-15       Impact factor: 3.468

10.  Incidence patterns of primary bone cancer in taiwan (2003-2010): a population-based study.

Authors:  Giun-Yi Hung; Jiun-Lin Horng; Hsiu-Ju Yen; Chueh-Chuan Yen; Wei-Ming Chen; Paul Chih-Hsueh Chen; Hung-Ta Hondar Wu; Hong-Jen Chiou
Journal:  Ann Surg Oncol       Date:  2014-04-11       Impact factor: 5.344

View more
  26 in total

1.  Characteristics and overall survival in pediatric versus adult skull base chordoma: a population-based study.

Authors:  Jordan C Xu; Brandon M Lehrich; Tyler M Yasaka; Brendan M Fong; Frank P K Hsu; Edward C Kuan
Journal:  Childs Nerv Syst       Date:  2021-01-18       Impact factor: 1.475

2.  Treatment of chordoma-where is it going?

Authors:  Norio Yamamoto; Hiroyuki Tsuchiya
Journal:  J Spine Surg       Date:  2019-09

3.  High dose image-guided, intensity modulated radiation therapy (IG-IMRT) for chordomas of the sacrum, mobile spine and skull base: preliminary outcomes.

Authors:  Andre Tsin Chih Chen; Carlos Bo Chur Hong; Douglas Kenji Narazaki; Virginio Rubin; Alexandre Ruggieri Serante; Ulysses Ribeiro Junior; Luiz Guilherme Cernaglia Aureliano de Lima; Brian Guilherme Monteiro Marta Coimbra; Alexandre Fogaça Cristante; William Gemio Jacobsen Teixeira
Journal:  J Neurooncol       Date:  2022-04-22       Impact factor: 4.130

Review 4.  Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective.

Authors:  Preantha Poonan; Clement Agoni; Mahmoud A A Ibrahim; Mahmoud E S Soliman
Journal:  Protein J       Date:  2021-09-29       Impact factor: 2.371

5.  Rare germline variants in PALB2 and BRCA2 in familial and sporadic chordoma.

Authors:  Bing Xia; Kajal Biswas; Tzeh K Foo; Thiago T Gomes; Maximilian Riedel-Topper; Eileen Southon; Zhihua Kang; Yanying Huo; Susan Reid; Stacey Stauffer; Weiyin Zhou; Bin Zhu; Hela Koka; Sally Yepes; Seth A Brodie; Kristine Jones; Aurelie Vogt; Bin Zhu; Brian Carter; Neal D Freedman; Belynda Hicks; Meredith Yeager; Stephen J Chanock; Fergus Couch; Dilys M Parry; Alvaro N Monteiro; Alisa M Goldstein; Marcelo A Carvalho; Shyam K Sharan; Xiaohong R Yang
Journal:  Hum Mutat       Date:  2022-07-12       Impact factor: 4.700

6.  Revision surgery for incomplete resection or recurrence of cervical spine chordoma: a consecutive case series of 24 patients.

Authors:  Peter Obid; Tamás Fekete; Philipp Drees; Daniel Haschtmann; Frank Kleinstück; Markus Loibl; Dezsö Jeszenszky
Journal:  Eur Spine J       Date:  2021-08-02       Impact factor: 3.134

Review 7.  Radiation therapy strategies for skull-base malignancies.

Authors:  J D Palmer; M E Gamez; K Ranta; H Ruiz-Garcia; J L Peterson; D M Blakaj; D Prevedello; R Carrau; A Mahajan; K L Chaichana; D M Trifiletti
Journal:  J Neurooncol       Date:  2020-08-12       Impact factor: 4.130

8.  Surgical and Functional Outcomes of En Bloc Resection of Sacral Chordoma: a Retrospective Analysis.

Authors:  Rohit Sharma; Debashish Mukherjee; Amiy Arnav; R Shankaran; Varun Kumar Agarwal
Journal:  Indian J Surg Oncol       Date:  2021-11-19

Review 9.  Recent advances in understanding and managing chordomas: an update.

Authors:  Scott W Connors; Salah G Aoun; Chen Shi; Valery Peinado-Reyes; Kristen Hall; Carlos A Bagley
Journal:  F1000Res       Date:  2020-07-16

10.  Computational Drug Repositioning Identifies Potentially Active Therapies for Chordoma.

Authors:  Jeffrey I Traylor; Hadley E Sheppard; Visweswaran Ravikumar; Jonathan Breshears; Shaan M Raza; Charles Y Lin; Shreyaskumar R Patel; Franco DeMonte
Journal:  Neurosurgery       Date:  2021-01-13       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.